Original Article

# **Evaluation Time as Most Effective Factor in Success of Thrombolysis with Streptokinase in Patients with Acute STEMI During COVID 19 Pandemic**

Saeed Ahmed<sup>1</sup>, Burhan ul Haq Muhammad Saqib<sup>1</sup>, Tahmeena Sarafaraz<sup>4</sup>, Shahzeb Saeed<sup>2</sup>, Muhammad Shoaib<sup>2</sup> and Asnad<sup>3</sup>

Time as Most Effective Factor in Success of **Thrombolysis** with Streptokinase with Acute **STEMI During COVID 19 Pandemic** 

# **ABSTRACT**

Objective: The objective of this study to evaluate time as most effective factor in success of thrombolysis with streptokinase in patients with acute STEMI during covid 19 pandemic.

Study Design: Prospective observational study

Place and Duration of Study: This study was conducted at the Kashmir institute of Cardiology, Mirpur Azad Jammu and Kashmir, from April 2020 to December 2020 for a period of nine months.

Materials and Methods: Patients presenting in emergency department with Acute STEMI were included, patients were analyzed via history, clinical examination and ECG findings of Acute STEMI.

**Results:** Total of 110 patients were included in study. 80% (88) patients were male and 20%(22) patients were female. Which shows increase in the number of female patients with acute STEMI In this study we have tried to compare ECG based success criterion with international data and our data back in 2016. During the study we found successful thrombolysis around 45% during covid 19 pandemic.

Conclusion: Time from onset of symptoms of Acute STEMI and start of streptokinase treatment was proven to be most effective method to improve the chances of success of streptokinase treatment and reduce mortality in such patients, as regard to my previous study in 2016 in same institute success of thrombolysis was markedly reduced with streptokinase during the covid 19 pandemic using the same treatment parameters.

Key Words: ST-segment elevation myocardial infarction, Streptokinase, time to streptokinase treatment, Covid-19.

Citation of article: Ahmed S, Saqib BM, Sarafaraz T, Saeed S, Shoaib M, Asnad. Evaluation Time as Most Effective Factor in Success of Thrombolysis with Streptokinase in Patients with Acute STEMI During COVID 19 Pandemic. Med Forum 2022;33(3):116-118.

## INTRODUCTION

ST segment elevation myocardial infarction is one of the most serious types of acute coronary syndrome that is related with very high mortality if there is delay in treatment.1

Decreased mortality in last decade is due to this known factor of delayed treatment causes high mortality has led to formation of ICUs equipped with advanced and

- <sup>1.</sup> Department of Cardiology / Community Medicine<sup>2</sup> / Biochemistry<sup>3</sup>, Mohtarma Benazir Bhutto Shaheed Medical College, Mirpur, AJK.
- <sup>4.</sup> Department of Obs / Gynae, Mohi-ud-Din Islamic Medical College, Mirpur AJK.

Correspondence: Dr. Asnad, Associate Professor of Biochemistry, Mohtarma Benazir Bhutto Shaheed Medical College, Mirpur, AJK.

Contact No: 0332-3698204 Email: drasnadkhan@gmail.com

Received: September, 2021 Accepted: December, 2021 Printed: March, 2022

early care using strategies like emergency percutaneous coronary inhtervention.2

Rupture of atherosclerotic plaque within coronary arteries resulting in exposure of injured vessel wall to coagulating factors in the blood resulting in thrombus formation is one of the most common causes of STEMI.3 Time is most efficient factor. Starting the streptokinase treatment in less than 30 minutes helps establish the blood flow to the compromised heart muscles. Each Delay of 30 minutes increases the relative risk of 1 year death by approximately 8% <sup>4,5</sup>.

Success of thrombolysis clinically is evident with resolution of symptoms of MI, more than 70% resolution of ST segment elevation and by runs of slow VT also called idioventricular rhythm.6

ECG is a very quick test to establish diagnosis of ST segment elevation myocardial infarction<sup>7,8</sup>.

STEMI is defined as 4th universal definition; ST elevation of more than 0.25mv in leads V2 and V3 in males less than 40 years, ST elevation of more than 0.20mv in males more than 40 years and ST elevation of more than 0.15mv in females is termed as acute STEMI.9

The objective of this study is to determine the time as most effective factor in success of thrombolysis with streptokinase in patients with acute STEMI during covid 19 pandemic.

#### MATERIALS AND METHODS

This observational study was conducted in emergency and CCU department of KIC, Mirpur Azad Jammu and Kashmir from April 2020 to December 2020 after approval from hospital ethical committee. Patients of ages 20-85 years with symptoms and ECG changes of acute MI are included in this study. exclusion criterion were ages <20 and >85, previous intracranial hemorrhage, known cerebral vascular lesion, known malignant intracranial neoplasm, suspected aortic dissection, active bleeding, significant close-head or facial trauma in last 3 months, recent surgery within 3 months. Informed verbal consent was taken from all patients. First patient was given Asprin 300mg and clopidogrel 300mg along with enoxaparin 1-2mg/kg once and after this streptokinase was administered in next 1 hour. ECG done at baseline and at 90 minutes was checked for ST resolution.

**Statistical Analysis**: SPSS for Windows version 20 (SPSS, Inc., Chicago, IL, USA) was employed for all statistical analyses.

#### RESULTS

Total of 110 patients were included in study. 80% (88) patients were male and 20% (22) patients were female.

Table No.1: Distribution by Gender

	Number of patients	Percentage		percentage of patient in 2016
Male	88	80%	72	82.8%
Female	22	20%	14	16.1%
Total	110	100%	87	100%

**Table No.2: Distribution by Age** 

	No. of patients	%age	Number of patients in 2016 study	%age of patients in 2016 study
Age 20-39 years	10	9.5%	5	5.6%
Age 40-59 years	45	40%	41	46%
Age 60-70 years	45	40%	38	42.7%
Age 70-85 years	10	9%	5	5.6%
Total	110	100%	89	100%

It shows increase in the number of female patients with acute STEMI In this study we have tried to compare ECG based success criterion with international data and our data back in 2016. During the study we found successful thrombolysis around 45% during Covid 19 pandemic.

Table No.3: Parentage by success of thrombolysis

	No. of Patients in this study	%age in this study	Frequency of patient in 2016 study	%age in 2016 study
Successful	50	45%	49	55%
Failed thrombolysis	60	55%	40	45%
Total	110	100%	87	100

#### DISCUSSION

Since last century streptokinase has proven to be cheap and effective way to treat STEMI<sup>10-13</sup>. In our study we tried to compare time to treatment with streptokinase success in patient with acute STEMI before covid 19 and during covid 19 pandemic.

In this study we have tried to compare ECG based success criterion with international data and our data back in 2016.

In our study in 2016 we had 87 patient with acute MI, 72 were male and 14 were female which makes it a 82.8% male patients and 16.1% female patients. While in this study we had 110 patient out of which 88 or 80% were male and 22 patients or 20% were females. Which shows increase in the number of female patient with acute STEMI.

Successful thrombolysis was seen in 55% of patient with acute STEMI in 2016 study, while recent study during covid 19 pandemic showed less number of successful thrombolsis around 45%.14 -17Percentage of acute STEMI in ages 40-59 years also increased from 40% to 46%. There was also an increase in number of STEMI cases at ages 60-70 years which increase from 38% to 42.7%. while in ages 71 to 85 years number of STEMI had seen a significant drop from 9 to 4.6%.11,12A study by fanaroff and Garcia published in JAMA also showed same results, there was increased number of patients with more ischemic time possibly due to late presentation and had more complications. Age distribution of patient compared to our study in 2016<sup>18-21</sup> was also changes, there were more number of young males, number of MI increased in ages 20-39 from 5.6% to 9%.

# **CONCLUSION**

Based on above mention facts, our own data comparison along with comparison with international data. It is clear that Covid 19 has increased the burden of acute STEMI and more patient have ended up with more complications and decreased number of successful thrombolysis in acute STEMI patient during Covid 19 pandemic points towards either late

presentation of patients or possible more clotting issues that are known to be related to covid 19 virus despite same protocol for streptokinase.

#### **Author's Contribution:**

Concept & Design of Study: Saeed Ahmed

Drafting:

Data Analysis:

Burhan ul Haq Muhammad Saqib, Tahmeena Sarafaraz Shahzeb Saeed,

Muhammad Shoaib, Asnad

**Revisiting Critically:** 

Saeed Ahmed, Burhan ul Haq Muhammad Saqib

Final Approval of version: Saeed Ahmed

**Conflict of Interest:** The study has no conflict of interest to declare by any author.

## **REFERENCES**

- 1. Levine GN, Bates ER Blackship JC, et al:2011 ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: executive summary: A report of American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular and angiography and intervention. Circulation 124:2574, 2011.
- 2. Jollis Jg, granger CB, Henry TD, et al: systems of care for ST segment elevation myocardial infarction: A report from American heart association mission: Lifeline program 2012;5:423.
- 3. Menon V, Harrington RA Hochman JS. Thrombolysis and adjunctive therapy in acute myocardial infarction: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:549-575.
- 4. O'gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guidelines for management of ST elevation myocardial infarction: A report of the American college of Cardiology Foundation/ American heart association Task force of practice guidelines. JAM Coll Cardiol 2013;61:e78.
- 5. Krumholz HM, Herron J, miller LE, et al. improvement in door to balloon time in United States, 2005 to 2010. Circulation 2011;124:1038.
- 6. Khan A, Nadeem S, et al. Is accelerated idioventricular rhythm a good marker for reperfusion after streptokinase. Ind heart J 2016; 68(3):302–305.
- Ahmad M, Yasir M, Rahmat A. Acute ST Elevation Myocardial Infarction; 70% OR More ST Segment Resolution on 90 Minutes Post Thrombolysis Electrocardiogram as a Predictor of In-Hospital Outcomes. Prof Med J 2018;25(5): 777-83.

- 8. Farooq U, Syed Nauman Ali, Hashmi KA. Validation of ECG criteria of successful thrombolysis. Pak Heart J 2015;48(1).
- 9. O'Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78
- 10. Gillis JC, Goa KL, et al. Streptokinase, A pharmacoenomic appraisal of its use in management of acute myocardial infarction, pharmacoeconomics.1996 sep;10(3?):281-310.
- 11. Fanaroff AC, Garcia S, et al. Myocardial Infarction during Covid 19 pandemic. JAMA 2021;326(19): 1916-1918.
- 12. Kumar N, Verma R, et al. Acute myocardial infarction in COVID-19 patients. A review of cases in the literature, Arch Med Sci Atheroscler Dis 2021;6:e169–e175.
- 13. Alam S, Mahmood R, et al. Lectrocardiographic success of thrombolysis with streptokinase administration in patients with Acute ST Elevation Myocardial Infarction admitted in Emergency Department of Kashmir Institute of Cadiology. IJBPAS 2020;9(11):3105-3112.
- 14. Catanese L, Tarsia J, Fisher M (3 February 2017). Acute Ischemic Stroke Therapy Overview. Circ Res 120 (3): 541–558.
- 15. Alexander T, Mehta S, Mullasari A, Nallamothu SK. Systems of care for ST-elevated myocardial infarction in India. Heart 2012;96:15–7.
- 16. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 16 randomized trial. Lancet 2003;361:13–20.
- 17. Xvier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): A prospective analysis of registry data. Lancet 2008; 371:1435–42.
- Mohanan PP, Mathew R, Harikrishnan S, Krishnan MN, Zachariah G, Joseph J, et al. Presentation, management and outcomes 25748 acute coronary syndrome admission in Kerala, India: Result from Kerala ACS registry. Eur Heart J 2013;34:121–9.
- Murry CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden disease study. Lancet 1997; 349:291-300.
- Gupta A, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiological and causation of coronary heart disease and stroke in India. Heart J. 2008;94: 16–21.